Mechanisms of Action Involved in Ozone Therapy: Is healing induced via a mild oxidative stress? by Sagai, Masaru & Bocci, Velio
REVIEW Open Access
Mechanisms of Action Involved in Ozone
Therapy: Is healing induced via a mild
oxidative stress?
Masaru Sagai
1 and Velio Bocci
2*
Abstract
The potential mechanisms of action of ozone therapy are reviewed in this paper. The therapeutic efficacy of ozone
therapy may be partly due the controlled and moderate oxidative stress produced by the reactions of ozone with
several biological components. The line between effectiveness and toxicity of ozone may be dependent on the
strength of the oxidative stress. As with exercise, it is well known that moderate exercise is good for health,
whereas excessive exercise is not.
Severe oxidative stress activates nuclear transcriptional factor kappa B (NFB), resulting in an inflammatory response and
tissue injury via the production of COX2, PGE2, and cytokines. However, moderate oxidative stress activates another
nuclear transcriptional factor, nuclear factor-erythroid 2-related factor 2 (Nrf2). Nrf2 then induces the transcription of
antioxidant response elements (ARE). Transcription of ARE results in the production of numerous antioxidant enzymes,
such as SOD, GPx, glutathione-s-transferase(GSTr), catalase (CAT), heme-oxygenase-1 (HO-1), NADPH-quinone-
oxidoreductase (NQO-1), phase II enzymes of drug metabolism and heat shock proteins (HSP). Both free antioxidants
and anti-oxidative enzymes not only protect cells from oxidation and inflammation but they may be able to reverse the
chronic oxidative stress. Based on these observations, ozone therapy may also activate Nrf2 via moderate oxidative
stress, and suppress NFB and inflammatory responses. Furthermore, activation of Nrf2 results in protection against
neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases. Mild immune responses are induced via
other nuclear transcriptional factors, such as nuclear factor of activated T-cells (NFAT) and activated protein-1 (AP-1).
Additionally, the effectiveness of ozone therapy in vascular diseases may also be explained by the activation of
another nuclear transcriptional factor, hypoxia inducible factor-1a (HIF-1a), which is also induced via moderate
oxidative stress. Recently these concepts have become widely accepted. The versatility of ozone in treating vascular
and degenerative diseases as well as skin lesions, hernial disc and primary root carious lesions in children is
emphasized. Further researches able to elucidate whether the mechanisms of action of ozone therapy involve
nuclear transcription factors, such as Nrf2, NFAT, AP-1, and HIF-1a are warranted.
Keywords: ozone therapy, oxidative stress, NFκB activity, Nrf2 activity, antioxidant response element (ARE), nuclear
factor of activated T cells (NFAT), activated protein-1 (AP-1), hypoxia inducible factor-1α (HIF-1α)
Introduction
Ozone therapy, or more specifically, the major ozonated
autohemotherapy (O3-AHT), has been used for almost
40 years. The first report on ozone therapy was pub-
lished by Wolff in 1974 [1]. Although ozone therapy is
now used all over the world, it has not yet been
accepted as orthodox medicine in all countries.
About two decades ago, both nitrogen oxide (NO) and
carbon monoxide (CO) were only considered as toxic
air pollutants or gases derived from cigarette smoke.
However, today, they are regarded to as essential gases,
since both NO and CO are responsible for very impor-
tant physiological actions within the body [2-4]. Simi-
larly hydrogen sulfide, a toxic gas, is now used as a drug
for the treatment of osteoporosis [5,6]. Additionally, low
dose radiation was also reported to have beneficial
effects within radiated cells, in particular, by prolonging
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Thus, our understanding of toxic compounds and their
effects within the body appears to be constantly chan-
ging as we have realized that toxicity depends entirely
on the dosage.
Both exercise and caloric restriction are excellent
examples of the hormetic effect [8]. It is well known
that moderate exercise is beneficial for health. Further-
more, caloric restriction is also well known to delay dis-
ease onset and mortality [9], to promote health, and to
increase longevity by inducing sirtuin 1 (SIRT1), a gene
responsible for longevity [10].
One of the purposes of this review is to propose a
hypothesis on the mechanisms of action of ozone from
the view point of oxidative stress and nuclear transcrip-
tion factors, because oxidative stress acts as a second
messenger in various intracellular signaling pathways.
Furthermore, cells can quickly induce biological
responses against oxidative stress to maintain biological
homeostasis and adapt to such stresses. And, some
nuclear factors induce various biological responses
against oxidative stress.
The findings of animal experiments and studies on the
clinical applications of ozone therapy are included.
Additionally, we explore the possibility that the mechan-
isms of action of ozone therapy may be via the activa-
tion of antioxidant protection systems, where moderate
oxidative stress may induce the activation of nuclear
transcriptional factors such as nuclear factor-erythroid
2-related factor 2 (Nrf2), hypoxia inducible factor-1a
(HIF-1a), nuclear factor of activated T-cells (NFAT),
and activated protein-1 ( AT-1).
1. The ozone paradox: is ozone always toxic?
1.1. Reaction with ozone and biological components
Pryor et al [11] have previously described the mechan-
isms involved in ozone lung toxicity. Briefly, inhaled
ozone reacts with polyunsaturated fatty acids (PUFA),
which are found in the lipids of the alveolar lining layer
(ALL), to produce ozone-specific products, referred to
as lipid ozonation products (LOPs). Ozone can also
react with unsaturated fatty acids to produce Criegee
ozonide in the absence of H2O. However, in the pre-
sence of H2O, aldehydes and hydrogen peroxide (H2O2)
a r ep r o d u c e d[ 1 1 ] .S i n c eH 2Oi sa b u n d a n tw i t h i nt h e
pulmonary system, the main reaction with ozone will be
the formation of aldehyde and H2O2 products. The net
reaction is as follows:
PUFA + O3 +H 2O−−−−−−−−−− → aldehyd e 1+a l d e h yd e 2+H 2O2
LOPs are proposed to be the more likely species to act
as signal transduction molecules. These products may
activate specific lipases, such as phospholipase A2 or
phospholipase C, to release arachidonic acid (AA). In
fact, AA levels increase more than 10-fold in endobron-
chial washings obtained from rats exposed to 1.1 ppm
of ozone for 5 days [12]. The released AA can then be
converted into other chemical mediators, such as var-
ious prostaglandins (PGs) and platelet activating factors
(PAF), via cyclooxygenases (COXs) and lipoxygenases
(LOXs) to induce an inflammatory response. Further-
more, it has been reported that 4-hydroxynonenal (4-
HNE), the most toxic type of aldehyde [13,14] and
H2O2 [15,16], have the ability to partake in signal
transduction.
1.2. Effects of ozone on the airways: Airway
hyperreactivity and inflammation
Airway hyper reactivity is one of the earlier signs of
ozone inhalation. An increase in airway hyperreactivity
is accompanied by airway inflammation. These changes
are similar to those by cigarette smoking. Lin et al [17]
proposed the signaling mechanisms behind airway
inflammation induced via smoking. Briefly, it was
demonstrated that cigarette smoke extract (CSE) added
into a cell culture system of human tracheal smooth
muscle cells binds to Toll-like receptor 4 (TLR4). TLR4
then activates NADPH-oxidase via adaptor molecules,
such as MyD88, to produce reactive oxygen species
(ROS). Further, ROS activate mitogen activated protein
kinases (MAPKs), and MAPK phosphorylates IBa part
of the nuclear factor kappa B and IBa (NFB- IBa)
complex found in cytosol fractions. As a result NFBi s
released from the complex, and this free NFBe n t e r s
into nuclei to activate the COX2 gene. COX2 then pro-
duces PGE2, which stimulates a number of cytokines,
among which TNFa and IL-6. The eicosanoide and
cytokines then induce the airway inflammation during
the early stage of exposure. These reactions also occur
in airway epithelial cells, endothelial cells, and macro-
phages. This signaling cascade is also supported by the
findings of Williams et al. [18]. They demonstrated that
TRL2 or TLR4 knockout mice do not have airway
hyperreactivity and neutrophil infiltration even after an
exposure to ozone of 3 ppm. These observations
strongly suggest that there is a strong relationship
between inflammation and TLR.
There are good experimental [19,20] and clinical [21]
studies showing that exposure by inhalation to pro-
longed tropospheric ozone damages the respiratory sys-
tem and extra pulmonary organs. The skin, if
extensively exposed, may also contribute to the damage
[22,23]. Consequently the strong reactivity of ozone,
which has an electrochemical potential value, E°=
+2.076V, has contributed to establish the dogma that
ozone is always toxic and its medical application must
be proscribed. However it will be shown that this dogma
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the lung surface versus human blood. Obviously it must
be said that ozone must be never inhaled by anyone in
the clinic. However, it seems that ozone may be pro-
duced in our body similar to NO, CO and H2S: it has
been reported that antibody-catalyzed water-oxidation
pathway produced an additional molecular species with
a chemical signature to that of ozone [24]. This species
is also generated during the oxidative burst of activated
human neutrophils and during inflammation [25].
The fundamental points to consider are: the topogra-
phy, anatomical and biochemical characteristics of the
organs daily exposed to ozone versus the potent antioxi-
dant capacity of blood exposed to a small and precisely
calculated dose of ozone for a few minutes. It is clear
how the respiratory system undergoing a chronic oxida-
tive stress can release slowly, but steadily, a huge
amount of already mentioned toxic compounds able to
act locally and to enter the circulation and cause serious
damage.
1.3. Origin, distribution and fate of toxic compounds
released by the pulmonary system during and after
ozone exposure
At the airspace level, the alveolar cells are constantly
overlaid by a film composed of water, salts and a myriad
of biomolecules such as a profusion of surfactant phos-
pholipids and a very small amounts of proteins, lipophi-
lic and hydrophilic antioxidants. Any inspired gas,
depending upon its relative concentration and pressure,
must first dissolve into the aqueous layer before reach-
ing the alveolar microcirculation and the erythrocytes.
This process implies a physical transport regulated by a
pressure gradient and a diffusion process. On the other
hand, it is known that ozone, in contact with biological
water, does not follow Henry’s law and, although it is
ten fold more soluble than oxygen, it is not transferred
into the alveolar capillaries because it reacts immediately
with the biomolecules present in the Alveolar Lining
Layer (ALL). It must emphasized that the average thick-
ness of ALL is only 0.2 micron [26]. As it was hypothe-
sized [11], ozone does not penetrate the cells but
oxidizes available antioxidants and reacts instanta-
neously with surfactant’s polyunsaturated fatty acids
(PUFA) present at the interface to form Reactive Oxy-
gen Species (ROS), such as hydrogen peroxide and a
mixture of heterogenous LOPs including lipoperoxyl
radicals, hydroperoxides, malonyldialdeyde, isoprostanes,
the ozonide and alkenals, particularly 4-HNE [27-29].
As cholesterol is a component of the epitherial lining
fluids (ELF) and because its double bond is readily
attacked by ozone, it can give rise to biologically active
oxysterols [30,31] of which 3b-hydroxy-5-oxo-5,6-
secocholestan-6-al (CSeco) has been implicated in pul-
monary toxicity, Alzheimer’s disease and atherosclerosis.
The antioxidant capacity present in the human ALL is
extremely limited and, although different portions of the
respiratory tract may have different antioxidant levels,
these are always irrelevant in comparison to the amount
of antioxidants that, in blood, easily tame the ozone
reactivity. First of all, by considering the expanse of the
alveolar surface (1 m
2/ k gb o d yw e i g h t )i na7 0k g
human, it can be calculated that the normal volume of
ALL ranges only between 17 and 25 ml, whereas 5 L of
blood include about 2.7 L of plasma. Moreover, the ery-
throcyte mass, amounting to about 2.3 kg, has an enor-
mous antioxidant capacity due to hydro-lipophilic
antioxidants and enzymes able to reduce any antioxidant
in a few minutes [32]. Erythrocytes, via glucose-6-phos-
phate dehydrogenase activity in the pentose cycle, can
continuously supply NADPH-reducing equivalents. The
amount of plasma albumin acting as a “sacrificial com-
pound” against oxidants is impressive (99.9% higher
than in ALL). Moreover erythrocytes have a GSH con-
tent of about 2.2 mM (almost 800-fold higher than
plasma) and therefore they contain a huge reserve. In
the course of evolution, aerobic organisms have devel-
oped a sophisticated antioxidant system against oxygen
and, although about 2% of the inhaled oxygen generates
superoxide anion, this is normally neutralized at an
alveolar pO2 pressure of 100 mm Hg. It is useful, how-
ever, to bear in mind that rats inhaling pure oxygen
(alveolar pressure at about 700 mmHg) die within 60-66
h [33], Ozone is far more reactive than oxygen, and
breathing air containing 10.0 ppm ozone causes death
within 4 h in rats. In order to understand the effects of
a daily 8-hour ozone exposure (April-October), we need
to know the average environmental ozone levels that
vary considerably for many reasons. The US Clean Air
Act has set an ozone level of 0.06 ppm as an 8-h mean
concentration to protect the health of workers (U.S.
Environmental Protection Agency, 2005). Evaluation of
recent studies [34,35] allows establishing an average
environmental ozone concentration of 0.09 ± 0.01 ppm.
However, ozone concentration in urban air can exceed
0.8 ppm in high pollution conditions [27]. For 8 h at
rest (a tidal volume of about 10 l/min and a retention of
inspired ozone of no less than 80%), the ozone dose
amounts to 0.70-0.77 mg daily or 21.0-23.1 mg monthly.
This is likely the minimal ozone intake because physical
activity increases the volume of inhaled air and, at peak
time, the ozone levels can easily augment to 200-300
ppb, reducing pulmonary functions and enhancing the
risk of cardiovascular death [21,34-36]). Moreover, the
toxicity is certainly augmented by the presence of NO2,
CO, SO2 and particulate matters (PM10). On this basis,
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LOPs at the ALL level, after being minimally quenched
by the insufficient, antioxidants will act as cell signals
able to activate nuclear factor-kappa B (NF-B), NO-
synthase, some protein kinases, thus enhancing the
synthesis and release of TNFa,I L - 1 ,I L - 8 ,I F N g and
TGFb1a n dt h ep o s s i b l ef o r m a t i on of nitrating species.
With an increasing inflow into the alveolar space of
neutrophils and activated macrophages, a vicious circle
will start, perpetuating the production of an excess of
ROS including also hypoclorous acid [37,38]. Moreover,
during Summer, there is a continuous flow of ozone
entering the respiratory space and also the very fact that
ozone dissolves in the ALL and reacts immediately;
t h u s ,e v e r ys e c o n d ,m o r eo z o n er e a c t ss ot h a ti na6 -
month period the cumulative dose (likely up to 150-300
mg ozone) becomes really deleterious. Similarly several
months exposure to ozone or to a prolonged oxidative
s t r e s sd u et oac h r o n i ci n f l a m m a t o r yd i s e a s e( a t h e r o -
sclerosis, diabetes, cancer) can possibly raise 4-HNE
plasma levels up to 5-20 μM and, in spite of continuous
detoxification, they can exert pathological effects as
those observed in vitro studies performed with leukemic
cells [39], lens epithelial cells [40], Jurkat T cells [41]
and when testing cholesterol secoaldehyde (CSeco) in
cardiomyoblasts [31]. Interestingly, tolerance to ozone
or 4-HNE is far more easily achieved by small and
repeated oxidative stresses than after a continuous and
heavy oxidation [42,43]. On the other hand, a normal
endogenous 4-HNE level (0.1- 0.7 μM) appears to act as
a defensive agent against itself and other toxic com-
pounds [13,44]. Thus, the biological behavior of HNE is
an enlightening example of how the physiological serum
level of a potentially toxic aldehyde produced by the
normal peroxidation is proficiently used for maintaining
homeostasis.
Finally, it is worthwhile to mention that the vast skin
surface, possibly exposed for hours to ozone and UV
radiation, can contribute to the overall toxicity: several
studies performed by exposing hairless mice to ozone
have shown not only depletion of the skin antioxidants
but the induction of a remarkable oxidative stress
[22,23]. As a consequence, humans, living in hot coun-
tries and during summer, become particularly suscepti-
ble to ozone and UV irradiation. On the contrary, a
quasi-total (excluding the neck and the head) exposure
of human volunteers to a very low ozone concentra-
tion in a sauna cabin for 20 min results in a very tran-
sient increase of LOPs in the peripheral circulation
that exerts therapeutic effects in chronic limb ische-
mia’s patients [45,46] interpreted as due to an induc-
tion of antioxidant enzymes and HO-1. In conclusion,
although ozone is not the only culprit for adverse
health effects, it significantly contributes to exacerbate
respiratory illnesses and enhances mortality in about
40% of the total US population [21]. The problem is
linked to the abnormal ozone concentration of tro-
posheric ozone and to the continuously increased pro-
duction of noxious compounds due to the excess
burning of coal, oil and virgin forests. During this cen-
tury, if human activities continue to release in the
atmosphere the actual amount of global emissions, the
Earth will experience a new Paleocene-Eocene Thermal
Maximum or “af e v e rp e r i o d ” with dramatic conse-
quences. The overall toxicity, due to the constant
aggressiveness of ozone on lungs and partly on the
exposed skin, associated with the relative efficiency of
the detoxifying system, progressively overwhelmed by
the perennial stress, favours pathological effects such
as inflammation and cell degeneration particularly on
lungs, liver (fibrosis), heart, kidneys and brain [47,48].
Consequently vital organs can be envisaged to be sub-
jected to a kind of a “toxic rain” produced in the pul-
monary system. Obviously, this knowledge has
popularized the idea of ozone toxicity but, in the next
section, it will be clarified that the generalization of
this concept is incorrect.
2. How an appropriate ozone dose acts on human
blood?
During the period 1970-2000, the ozonated autohe-
motherapy had been performed in an empirical fashion
owing to imprecise ozone generators and the lack of
knowledge of the mechanisms of action of ozone in
human blood. However, by 1998, two crucial events
changed the outlook: firstly, new ozone generators with
precise photometers able to accurately measure (at
253.7 nm) the ozone concentration became available,
and secondly, it was clarified how ozone works when
mixed with blood ex vivo [49,50]. Oxygen equilibrates
with the extracellular and intraerythrocytic water before
becoming bound to hemoglobin until it is fully oxyge-
nated as shown by the rapid increase of the pO2 from
a b o u t4 0u pt o4 0 0m m H g .O z o n e ,t e nf o l dm o r e
hydrosoluble than oxygen, readily dissolves in the aqu-
eous environment of plasma and is partly (between 20
and 40%) quenched by hydrophilic antioxidants such as
reduced glutathione, ascorbic and uric acids acting as
sacrificial compounds, while the bulk reacts with PUFA
transported by the albumin. The “therapeutic window”
has been carefully determined and ranges between 10
and 80 μg/ml (0.21-1.68 μmol/ml) ozone per ml of
blood. It ensures a small and precise oxidative stress
able to elicit medical efficacy, but no toxicity. It must be
noted that ozone acts as a pro-drug because, during this
fast reactions, ozone disappears but generates two cru-
cial messengers: the first is H2O2 and the second is a
mixture of LOPs finally exemplified by 4-HNE (from
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from omega-3 PUFA).
The behavior and pharmacodynamic of H2O2 have
been ascertained: the initial formation of a gradient
between plasma and intracellular water [51] allows its
entrance into the erythrocytes, lymphocytes and plate-
lets, but its concentration remains around a few micro-
moles because it is quickly reduced to H2Ob yf r e e
GSH, catalase and GSH-Px [52]. Its half-life is less than
60 seconds and yet its intracellular concentration is cri-
tical, because in order to activate some biochemical
pathways (formation of GSSG with consequent activa-
tion of the pentose cycle in the red cell and activation
of a tyrosine kinase in lymphocytes), it must reach a cri-
tical threshold that, nonetheless, is not cytotoxic. The
concept of threshold is physiologically important and
means that an ozone dose below 10 μg/ml of gas per ml
of blood, in most cases, is biologically ineffective
b e c a u s et h eo z o n ed o s ei st o t a l l yn e u t r a l i z e db yt h e
plasma antioxidants. In other words, the concept of a
threshold helps to understand that a too low ozone dose
may be ineffective (placebo effect) while a dose higher
than the therapeutic one can be toxic. It is almost need-
less to add that saline-washed erythrocytes suspended in
saline, even if exposed to very low ozone concentrations,
undergo conspicuous hemolysis, an artificial result [53]
that has favoured the concept of ozone toxicity. Pro-
vided that the ozone dose is within the well defined
range, there is only a transitory decrease (no more than
25%) of the potent antioxidant capacity of plasma [54]
fully reconstituted within 20 min owing to the efficiency
of the redox system [32]. There is neither damage to
erythrocytes nor to other cells: hemolysis is negligible
(from 0.4 up to 1.2%), there is no leakage of K+ and
methemoglobin remains normal [55]. It must be added
that ozonated erythrocytes show an improved glycolysis
with an increase of ATP and 2,3-DPG levels, which are
able to shift the dissociation curve of HbO2 to the right,
confirming the observation of an improved delivery of
oxygen in peripheral obstructive arterial disease. Exten-
sive data have been reported in reviews [56-58] and two
books [46,50]. It is now clear that a “physiological”
ozone dose (most frequently ranges between 20 and 40
μg/ml ozone per ml of blood) triggers an acute and pre-
cisely calculated oxidative stress able to activate several
biological processes summarized in Table 1. What hap-
pens during the rapid infusion of the hyperoxygenated-
ozonated blood into the donor ? The hyperoxygenation
of blood (pO2, at about 400 mmHg) is irrelevant
because, during the 15-min infusion period, it mixes
with venous blood so that the final venous pO2 relative
pressure is hardly modified. Oxygen-ozone behaves
similarly when this gas mixture comes in contact with
either a moist human skin [45] or the rabbit colon-
rectal mucosa [59], ozone dissolves immediately in the
water overlaying the epithelium and reacts with either
sebum, or mucoproteins, faeces and any other biomole-
cules present in the liquid film generating hydrogen per-
oxide and LOPs. Only LOPs are absorbed via lymphatics
and venous capillaries and reach first the liver and then
enter into the general circulation where these have been
measured [59].
The next important step was to evaluate the distribu-
tion, the fate and the biological significance of alkenals.
After the 5 min mixing blood with the gas mixture ex
vivo, the ozonated blood is ready to be infused back into
the donor patient. Both ozone and hydrogen peroxide
have been exhausted but alkenals have formed adducts
with either the Cyst 34 of albumin or/and GSH and will
be infused into the patient’s circulation. They will inter-
act with endothelial cells and then with billions of cells
of various organs [46]. Just in case an inexpert ozone
therapist uses an excessive ozone dose, he may oxidize
Cys 34 to sulfenic acid: RSOH, which however can be
reduced again.
The distribution of 4-HNE and similar alkenals has
pharmaco-toxicological relevance: owing to the intrinsic
toxicity of aldehydes, it is important to know their meta-
bolism and fate: Alary et al. [60] have reported that
about 70% of 4-HNE is excreted in urine within 2 days
after its intravenous administration in rats. Siems and
Grune [61], after investigating the metabolism of 4-HNE
in several mammalian cells and organs, demonstrated
that 4-HNE, at a concentration of 100 μM, was
degraded within 3 min of incubation at 37°C, and it
took only 10-30 s to restore the physiological level of
about 0.2 μM. The kinetic of disappearance from mildly
ozonated blood of thiobarbituric acid reactive substances
(TBARS), including MDA and 4-HNE has been mea-
sured in six patients with age-related macular degenera-
tion (ARMD), and their half-life was equivalent to 4.2 ±
1.7 min [62]. On the other hand, when the same sam-
ples were incubated in vitro (at 37°C and pH 7.3), LOPs
Table 1 Ozone therapy can induce the following
biological responses
a) Improves blood circulation and oxygen delivery in ischemic tissue
owing to NO, CO, and increase levels of intra-erythrocytic 2, 3-DPG.
b) Enhances general metabolism by improving oxygen delivery.
c) Upregulates cellular antioxidant enzymes and induction of HO-1
and HSP70.
d) Induces a mild activation of the immune system and enhances the
release of growth factors.
e) Does not procure acute or late side effects.
f) Procures a surprising wellness in most patients, probably via the
stimulation of the neuroendocrine system.
g) Activates neuroprotective systems.
References: [46,58,81,84,119]
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their stability in an acellular medium and suggesting the
relevance of cellular catabolism [49]. On the whole, it
appears that mammals have developed an efficient
detoxification machinery to metabolize 4-HNE and
minimize its toxicity: Awasthi et al. [42] not only have
indicated six enzymes: glutathione S-transferases, aldo-
ketoreductases, aldose reductase, aldehyde dehydro-
genases Cyp450 4A and b-oxidation enzymes, important
in the metabolism of 4-HNE, but they and other authors
[40,43,44] have emphasized that 4-HNE stress-precondi-
tioned cells can develop a significant adaptive response
by upregulating the synthesis of g-glutamate cysteine
ligase, g-glutamyltransferase, g-glutamyl transpeptidase,
HSP-70, heme oxygenase-1 and a variety of antioxidant
e n z y m e s .T h e r ei sn o wa m p l ec o n s e n s u so nt h ei m p o r -
tance of the induction of cell tolerance to submicromo-
lar levels of 4-HNE [13,63-66]. At this point, it seems
useful to point out that mammalian organisms, for con-
trolling 4-HNE toxicity due to oxidative stress and
maintaining it at physiological plasma level of 0.3-0.7
μM enact the following processes:
a) Dilution, a simple calculation indicates that a
bolus injection of a dose of 500 μM 4-HNE in 10 ml
of plasma, once diluted in a plasma-extracellular
fluid volume of 12 l, irrespective of any other pro-
cess, yields a concentration of as low as 0.04 μM.
b) Detoxification, due to the direct inactivation of 4-
HNE with GSH and ascorbate or to the interaction
with billions of cells endowed with detoxifying
enzymes [42]
c) Excretion, into bile and urine after hepatic detoxi-
fication [67] and renal excretion [60], and
d) Cell internalization,t h i si sac r u c i a la n di n t e r e s t -
ing point because the consequent biological effects
can be either negative or positive. Several months
exposure to inhaled ozone or to a prolonged oxida-
tive stress due to a chronic disease (atherosclerosis,
diabetes, inflammation) can possibly raise 4-HNE
plasma levels up to 5-20 μM and, in spite of contin-
uous detoxification, they can exert pathological
effects. Interestingly, tolerance to ozone or to 4-
HNE is far more easily achieved by small and
repeated oxidative stresses than after a continuous
and heavy oxidation [42.43]. On the other hand, a
normal endogenous 4-HNE level (0.1- 0.7 μM)
appears to act as a defensive agent against itself and
other toxic compounds. At this stage, alkenals
acquire the great value to hypothetically trigger the
molecular mechanisms leading to elicit medical effi-
cacy without toxicity. This aspect is discussed in the
next section.
3. Oxidative stress and nuclear transcriptional
factors in carcinogenesis
Chronic inflammation plays a critical role in neoplastic
growth (transformation), as well as in many other dis-
eases. Inflammation is induced via NFB activation by
various inflammatory factors, such as LPS and severe
oxidative stress derived from drugs that induce iNOS,
COX-2, and inflammatory cytokines. These factors
induce the survival, growth, and proliferation of tumor
cells, and result in neoplasia [68]. Therefore, inhibition
of NFB is an important target for the prevention and
treatment of cancer. For example, it is known that the
inhibitors of NFB, such as vitamin E, resveratrol, cur-
cumin, catechin, and aspirin may delay or suppress
tumor growth.
3.1. Anti-neoplastic mechanisms of Nrf2
Chronic inflammation plays a critical role in neoplastic
growth as well as in many other inflammatory diseases.
Therefore inhibition of NFkB is an important target for
the prevention and possibly treatment of cancer. Has
Nrf2 a role in ozone therapy ? Li et al [69] demon-
strated that Nrf2, an important cytoprotective nuclear
transcription factor, suppresses NFB-activation. As
shown in Fig.1(left side), Nrf2 is usually present within
the cytosol as a complex with Keap-1 protein. The ques-
tion is: are alkenals able to dissociate this complex ? The
Keap-1 protein has two SH-groups and the formation of
adducts may cause a conformational change favoring its
dissociation. Besides other pathways to be experimented
and a mild oxidative stress, Nrf2 is released from this
complex and is transported into nucleus. The trans-
ported Nrf2 forms a new complex with Maf protein,
and induces the transcription of various antioxidant and
phase II detoxification enzymes by binding to antioxi-
dant response element (ARE) on DNA. The specific
antioxidative enzymes that are activated, include SOD,
catalase (CAT), GSH, GSH-reductase, GPx, GSH-S-
transferase (GSTr), HO-1, NADPH quinine-oxidoreduc-
tase 1 (NQO1), heat shock protein 70 (HSP70), and
phase II enzymes. These enzymes may elicit anti-neo-
plastic effects.
Sulforaphane (SFN), a component in broccoli is the
most common phytochemical that induces the transcrip-
tion of various antioxidant enzymes via the activation of
Nrf2. In fact, SFN alone may also act as an oxidative
stressor in cells.
3.2. Anti-neoplastic phytochemicals are not effective in
Nrf2 knockout mice
In the previous section, the anti-neoplastic effects of
phytochemicals, such as SFN, have been explained with
respect to their via activation of Nrf2. It is well known
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through the induction of cellular detoxifying/antioxidant
enzymes via the Nrf2 [70]. If these effects are really
mediated via Nrf2, then the actions of SFN should be
inactived in Nrf2 knockout mice, and active in wild-type
mice. Indeed, this observation was made by Xu et al
[68] when they examined the chemopreventive efficacy
of SFN in Nrf2 wild type (+/+) and Nrf2 knockout (-/-)
mice. A topical application of 100 nmol of SFN once a
day for 14 days prior to 7,12-dimethyl-benz(a)anthra-
cene/12-O-tetradecanoyl-phorbol-13-acetate treatments
decreased the incidence of skin tumors in the Nrf2
(+/+) mice compared to the vehicle-treated group. More
importantly, there were no chemopreventive effects eli-
cited by SFN pre-treatment in Nrf2 (-/-) mice. Taken
together, these results demonstrate, for the first time,
that Nrf2 (-/-) mice are more susceptible to skin tumor-
igenesis, and that the chemopreventive effects of SFN
are mediated via Nrf2 activation.
3.3. Oxidative stress induced by moderate exercise
induces Nrf2 -activation
Moderate and severe exercise results in the production
of ROS in both muscle and internal organs. ROS are
not only toxic, but also play an important role in cell
signaling and the regulation of gene expression.
Moderate exercise is known to be good for health, as
opposed to severe exercise. However, the mechanisms of
action of the ROS produced during exercise are not
fully understood.
The production of ROS during exercise is primarily
due to disorders of the mitochondrial electron transport
system induced via an increase in oxygen consumption,
elevations in NADPH-oxidase activity resulting from
ischemia and reperfusion of internal organs, and inflam-
mation induced via the infiltration of inflammatory cells,
such as macrophages and neutrophils. ROS production
levels may also depend on the intensity of exercise.
G o m e z - C a b r e r ae ta l[ 7 1 ]r e p o r t e dt h a tm o d e r a t e
exercise results in the activation of MAP kinases and
the NFB pathway, and consequently the expression of
eNOS, iNOS, and MnSOD. Interestingly, all of these
changes were abolished when ROS production was
inhibited with allopurinol, an NADPH-oxidase inhibitor.
These findings suggest that exercise-induced ROS pro-
duction results in the expression and activation of anti-
oxidant enzymes, such as MnSOD and GPx, primarily
via the activation of the NFB pathway. However, evi-
dence regarding the induction of antioxidant enzymes
via the NFB pathway is still lacking. Thus, we cannot
reject the possibility that Nrf2 is also activated. Thus, to
hypothesize that moderate exercises induces the
Maf
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NFǲB
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duction induces the activation of NFBa n dN r f 2m a y
be reasonable, but it remains to be clarified.
3.4. Biological responses induced via the activation of
Nrf2/Keap1/ARE
Nrf2 is activated by mild oxidative stress, and increases
the transcription of ARE [72,73]. This may be a possible
mechanism behind the anti-neoplastic effects of this
pathway. Other potential biological responses elicited via
an activation of the Nrf2/Keap1/ARE pathway are sum-
marized in Table 2. Items 1 to 7 were already discussed
by Dinkova-Kostova [74], whereas items 8 and 9 will be
discussed in the next sections.
3.5. Nrf2 is associated with apoptosis and DNA repair
Numerous reports suggest that oxidative stress induces
cell apoptosis, and antioxidants, such as increased levels
of HO-1, protect the cell against apoptosis. HO-1 is
induced by Nrf2, and prevents against apoptosis. For
example, the complex work of Brunt et al [75] demon-
strated that apoptosis of human vascular smooth muscle
cells is induced by H2O2, and that the activation of the
HO-1 promoter via Nrf2 protects these cells from the
apoptotic effects of H2O2. Furthermore, apoptosis
induced via either chromium (VI) [76] or LPS [77] also
protected by Nrf2-dependent HO-1 induction. These
findings suggest that anti-apoptotic effects are due to
the activation of antioxidant protection systems induced
via the activation of Nrf2.
Nrf2 has been also shown to be involved in DNA
repair (#9 in Table 2). Villeneuve et al [78] found that
Nrf2 is significantly associated with DNA repair. In fact,
both Nrf2 and p21 were found to regulate the fine bal-
ance between life and death by controlling ROS levels.
That is, the cytoprotective effects, specifically those con-
cerning DNA repair or apoptosis, are likely dependent
on the magnitude of oxidative stress. Therefore, p21-
mediated activation of the Nrf2 signaling pathway may
b et h ef i r s td e f e n s em e c h a n i s mu s e dt or e d u c eR O S
under low stress conditions. At low levels of oxidative
stress, p21 activates the Nrf2-dependent antioxidant
response, which protects the cell from ROS-induced cel-
lular damage. At moderate levels of oxidative stress,
which involves DNA damage, p21 induces cell cycle
arrest to allow for DNA repair. At high levels of oxida-
tive stress, or at the point of no return, Nrf2 is
destroyed, and thereby, the Nrf2-dependent pro-survival
response is inhibited, and the pro-apoptotic response
initiates apoptosis.
In conclusion, the Nrf2-dependent antioxidant
response has been shown to protect against oxidative-
stress related diseases, such as cancer [79,80] neurode-
generative diseases [81,82], cardiovascular disease
[83-85], lung emphysema [86], inflammation [87,88] and
aging [89]. This background will be useful for evaluating
the role of Nrf2, but its actual relevance remains to be
demonstrated by selected experiments connected with
ozone therapy.
4. Biological responses and therapeutic effects
induced by ozone therapy
The versatility of ozone therapy applications is impress-
ive but there are some limitations, and therefore ozone
therapy is not a panacea. From the available data, vascu-
lar and some degenerative diseases are the most suitable
to be treated, while acute and chronic infectious diseases
such as HIV infection and chronic hepatitis C cannot be
cured with ozone therapy, because both viruses and
other pathogens, either free in the plasma or/and pre-
sent insides cells, cannot be inactivated by the ozone
messengers and actually are well protected by the potent
antioxidant capacity of blood.
4.1. Clinical results in peripheral obstructive arterial
diseases (POAD)
Since the initial work of Rokitansky [90], several small
clinical studies have been performed on POAD showing
a consistent improvement of the local circulation after a
cycle of 13-18 ozonated AHT [reviewed in Bocci, 46]. It
is well known that even a modest obstruction of limb
arteries due to atherosclerosis, diabetes, or Buerger’s dis-
ease (thromboangiitis obliterans) leads to a progressive
reduction of blood flow to the limb.
Tissue ischemia and any minor trauma facilitate the
formation of an ulcer, which will no heal because of
reduced oxygenation, lack of nutrients and growth fac-
tors indispensable for the repair process. Ozone therapy
firstly lead to the activation of glycolysis with an
Table 2 Biological responses induced via the activation
of Nrf2/ARE with mild oxidative stress
1) Increasing the levels of direct antioxidants, such as GSH, CO, and
bilirubin.
2) Stimulating GSH regeneration via glutathione and thioredoxin
reductase.
3) Increasing the levels of enzymes that detoxify oxidants and
electrophils (i.e. catalase, SOD, GPx, GSTr, NADPH-quinone
oxidoreductase (NQO1), HO-1, HSP70, etc).
4) Increasing the levels of phase II enzymes.
5) Inhibiting cytokine-mediated inflammation via the induction of
leukotriene B4 reductase.
6) Reducing iron overload, and subsequent oxidative stress induced via
elevated ferritin.
7) Recognizing, repairing, and removing damaged proteins.
8) Protection from apoptosis induced via oxidative stress*.
9) Increasing DNA repair activity*.
Ref from 1) to 7): Dinkova-Kostova AT [74].
References from 8) to 9) : Villeneuve NF. [78].
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diphoshoglycerate (2,3-DPG). Consequently the sigmoi-
dal oxygen-binding curve of Hb shifts to the right and
increases the release of oxygen in the ischemic tissues.
The modest but critical entrance of H2O2 in the ery-
throcyte is promptly reduced it to water through the
action of GSH. The increased formation of oxidized
GSH as GSSG alters the GSH/GSSG ratio but this
change is rapidly corrected by either expelling some of
the GSSG, or by reducing it via GSH-reductase at the
expense of either ascorbic acid or thioredoxin. It is
noteworthy that this critical recycling proceeds within 3
minutes [32]. Moreover the activation of glucose-6-
phosphate dehydrogenase (G6PDH) can provide redu-
cing power and activates glycolysis [91]. It must be
noted that the metabolic profile of ozonated blood is
practically over imposable with that of simply oxyge-
nated blood [92].
According to the Fontaine-Leriche classification,
patients at either stage II (intermittent claudication and
transitory pain), or stage III (continuous pain, cyanosis,
and possibly initial ulcers) achieve the best results. Stage
IV includes incipient necrosis of toes and unbearable
pain leads to surgical amputation that can be reduced
or delayed with ozonated-AHT in about 50% of cases.
In comparison to pentoxyfilline and prostanoids (the
gold standard of orthodox treatment), ozonated AHT
has proved more effective and without side effects in
ischemic vascular disease. There is no substantial differ-
ence in the results either using AHT or the extravascu-
lar ozonation of blood, which is an invasive and
expensive method. By using the former procedure
[93.94], 28 patients, randomized to either receive their
own ozonated blood or a cycle of prostacyclin infusion
were evaluated. All patients continued conventional
treatment with statins, anti-hypertensive and anti-plate-
let aggregation drugs. Ozone therapy proved more effec-
tive than prostacyclin in terms of pain reduction and
improvement of the quality of life, but no significant dif-
ference was seen in vascularization of the lower limbs in
either group, most likely due to the short duration of
treatment (14 treatments in 7 weeks). In this complex
pathology, more prolonged treatments asscociated with
topical therapy with ozonated oil may led to a satisfac-
tory healing of ulcers, because it is a mistake to stop
therapy too early. Actually this therapy should be con-
tinued for life with less frequent treatments. An
improved schedule on a trial in progress consists of two
ozonated-AHTs (225 mL blood plus 25 mL of 3.8%
sodium citrate solution), given weekly for at least 4
months. In patients at stage III and IV, the topical ther-
apy is most important when performed with ozonated
water and olive oil because it helps to accelerate healing
of ulcers. How well ozonated-AHT works it appears
evident by the fact that the nocturnal excruciating pain
disappears after the first two to three treatments, indi-
cating the improvement of blood flow in the ischemic
tissue and the lack of ‘’stealing’’ blood away from under-
perfused muscle.
An experimental confirmation of Nrf2 activity regard-
ing the positive mechanisms inducing the antioxidative
protection systems, is warranted. Furthermore, Nrf2
may be a potential mechanism involved in the upregula-
tion of cellular antioxidant enzymes and induction of
HO-1 and HSP70 (Table 1, c). It has been already
shown that therapeutic ozone concentrations can induce
both HO-1 and HSP70 [95], but the role of Nrf2
remains to be ascertained. It seems evident that the
therapeutic activity of ozone in POAD is due to an
improvement in blood flow and oxygen delivery in the
ischemic areas. Moreover it was recently demonstrated
that a nuclear transcription factor, hypoxia inducible
factor-1a (HIF-1a), may participate in improving the
outcomes of ischemic tissues [96-98]. HIF-1a,a nu b i -
quitously expressed molecule, regulates a number of
genes (i.e. hypoxia response elements, HREs) that elicit
compensatory responses during states of hypoxia, meta-
bolic compromise, and oxidative stress. Activation of
HIF-1a results in increases of vascular endothelial
growth factor (VEGF), erythropoietin (EPO), and glyco-
lytic enzymes, all of which enhance cell proliferation
and survival. Furthermore, an increase in the biosynth-
esis of VEGF can stimulate neoangiogenesis, and conse-
quentially improve blood flow, and increase the
biosynthesis of erythropoietin, which augments oxygen
delivery. An increase in glycolytic enzymes enhances
glucose metabolism, and consequently increases the bio-
synthesis of NO and CO, which also stimulate blood
flow and oxygen delivery into hypoxic tissues. Thus,
these biological responses may induce the excellent
therapeutic effects of ozone-induced mild oxidative
stress in POAD. Additionally, points a) and b) in Table
2 may be explained by the role of HIF-1a.I nt h en o r -
moxic state, HIF-1a is inactivated by proline hydroxy-
lases (PHDs) and VHL within the cytosol. On the other
hand, in hypoxia, PDHs and VHL are inactivated by
mild oxidative stress, and HIF-1a is released from PHDs
and VHL, transferred into nuclei, where HIF-1a forms a
heterodimer with HIF-1b, and results in the transcrip-
tion of hypoxia response elements (HREs) on DNA. It
w a sr e p o r t e dt h a ta b o u t2 0 0 0g e n e si nH R E sa r er e g u -
lated by HIF-1a [99] including genes involved in the
regulation of apoptosis, pH regulation, and proteolysis,
as well as angiogenesis, erythropoiesis and glucose meta-
bolism. Another remark regards the postulation that 4-
HNE reaching the bone marrow environment may favor
the release of staminal cells, which may be able to
switch on angiogenesis in the ischemic tissues. It is
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the near future.
Millions of people suffer from chronic limb, brain, and
heart ischemia, which represent the major cause of
death worldwide. This has a huge socio-economic
impact, particularly in the developing world. If only
orthodox medicine will accept ozonated AHT as an
adjunct to standard medication, a great leap forward
will be noted. It is most unfortunate that owing to the
lack of sponsors and funds it has not yet been possible
to carefully evaluate controlled clinical results in either
stroke or chronic heart failure patients
4.2. The relevance of ozone therapy in Age-Related
Macular Degeneration (ARMD)
In the UK alone, some 250,000 patients affected by the
‘’dry’’ (atrophic) form of ARMD are suitable for treat-
ment with ozonated AHT, but all over the world there
are more than 30 million people searching for a therapy.
Nonetheless, ophthalmologists can only prescribe anti-
oxidants and zinc, which are minimally effective. Since
1995, almost 1,000 patient with the dry form of ARMD
have been treated with ozonated AHT at the Siena
(Italy) polyclinic and three-quarters have shown an
improvement of one to two lines on the visual acuity
chart (reviewed in 46). Moreover it is relevant that the
disease does not progress during ozone therapy. Usually
15-18 treatments, at an initial ozone concentration of 20
mg/ml of gas per ml blood, slowly upgraded to 60 mg/
ml (twice weekly), followed by two monthly session as a
maintenance therapy, allows to maintain the improve-
ment. Although uncontrolled, this study emphasizes that
ozone therapy is the only treatment able to dramatically
improve the patient’s quality of life. In this disease there
is progressive degeneration and death of the fovea cen-
tralis photoreceptors and of the pigmented retinal
epithelium (PRE) as a consequence of several factors,
one of which is chronic hypoxia. Although O3-AHT
induces a pleiotropic response, the main advantage is
due to an increased delivery of oxygen to the retina,
which is the bodily tissue with the highest oxygen con-
sumption. It is worth noting that AHT is useless, even
harmful, in the exudative form of ARMD and in multi-
genic and progressive disorders (e.g., retinitis pigmen-
tosa and recessive Stargardt’sd i s e a s e ) .T h ee x u d a t i v e
form, characterized by an aberrant choroidal vascular
growth and a vascular hyper-permeability beneath the
retina and the PRE, is caused by worsened ischemia,
which stimulates the release of the vascular endothelial
growth factor [99]. In the exudative form it seems that
the intravitreous administration of anti-VEGF antibody
may temporarily slow down angiogenesis with a slight
functional improvement. It must be emphasized that
O3-AHT (in the dry form) noto n l yi m p r o v e sv i s u a l
activity but at least, in part, helps the patient to re-
acquire the capacity of autonomous life. Finally it is
interesting to inform that only during the last month a
preliminary trial evaluating whether the intravitreal
injection of staminal PRE in blind patients with Star-
gardt’s disease will be able to restore vision. Although
patients will receive an immunosuppressive therapy,
there are other risks but after ten years of preliminary
studies, the trial needed to be performed.
4.3. The effects of ozone therapy in diabetes
Diabetic nephropathy induced via diabetes mellitus is
linked with oxidative stress. The potential therapeutic
effects of ozone therapy were studied in streptozotocin
(STZ)-induced diabetic rats [100]. The induction of dia-
betes mellitus significantly elevated blood pressure,
HbA1c, BUN, creatinine, and renal tissue levels of
MDA, whereas SOD, CAT and GPx activities were sig-
nificantly reduced. Treatment with either insulin or
ozone therapy significantly reversed the effects of dia-
betes mellitus. Furthermore, a combination of both insu-
lin and ozone therapy even further reversed the effects
of diabetes mellitus in comparison to monotherapy.
Thus, ozone administration in diabetes mellitus rats
reduced levels of oxidative stress markers and improved
renal antioxidant enzyme activities, especially when rats
were treated with a combination of ozone and insulin.
This initial result suggested that ozone therapy may be
useful for treating diabetic patients, specifically by med-
iating antioxidative responses. Clinical evidence that
ozone therapy is useful has been anecdotically reported
several times by private ozone therapists but a valid,
controlled clinical trial has yet to be performed. Chronic
limb ischemia is often accompanied by type 2 diabetes
and these patients have been advantageously treated
with ozonated AHT [46]. The need of reducing the
insulin dose, suggesting either an improved insulin
secretion or/and an increased receptor sensitivity has
become a common observation.
As ozone is used in all Cuban hospitals, Cuban ozone
therapists have performed a randomized controlled clin-
ical trial in diabetic patients with peripheral arterial dis-
eases and diabetic foot [101]. One group (n = 51) was
treated with ozone administered via rectal insufflation of
2 0 0m lo fg a sw i t ha no z o n ed o s eo f1 0m gt o g e t h e r
with topical ozone both as gas and ozonated oil. The
control group (n = 49) was treated with systemic and
topical antibiotics. The efficacy of the treatments was
evaluated by comparing the glucose level, the area of
the ulcers and several biochemical markers after only 20
days of treatment. A drawback was the lack of a follow-
up after the 20 days therapy. The experimental group,
after receiving a total dose of 200 mg ozone showed an
improved glycemic control, a reduced oxidative stress,
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lesions without any side effects and with a fewer ampu-
tations than the control group. Human diabetic foot is a
chronic disease and these results are even more surpris-
ing not only because they were achieved only after 20
days therapy, but also because among the five routes of
ozone administration, [reviewed in 102], i.e.: (1) the
major and minor ozonated autohemotherapy; (2) the
extracorporeal circulation of blood against oxygen-
ozone; (3) the quasi-total body exposure to oxygen-
ozone; (4) the intracavitary, subcutaneous, intramuscular
administration, and (5) the ozone insufflation via rectum
is the most unreliable administration route because we
never know the percentage of the really effective ozone
dose insufflated into the rectum. Moreover in Europe at
least 40% of patients: (i) refuse the administration of
ozone via rectum; (ii) part of the ozone dose may be
unwillingly eliminated immediately after the gas intro-
duction; (iii) the fecal content and the abundant muco-
proteins certainly neutralize part of the ozone dose, and
(iv) in all cases ozone, unlike oxygen, is not absorbed by
the rectal mucosa. In previous rabbit experiments [59],
it was clarified that only peroxidation products could be
detected in portal blood. This is because ozone immedi-
ately reacts with a variety of biomolecules present in the
luminal content and only some of the generated com-
pounds are absorbed and may exert therapeutic activity.
The concentration of ozone (50 mg/ml) used in the
Cuban patients is too high and unwise because it can
cause painful intestinal cramps. Moreover it must keep
in mind that Eliakim et al. [103], after repeated enema
in rats with ozonated water, have reported the appear-
ance of a microscopic colitis. As a consequence, even
though results are spectacular, they need to be con-
firmed, not only by repeating the trial, but preferably by
using the reliable strategy of ozonated autohemotherapy
[104]. On this basis it appears urgent to organize an
appropriate clinical trial in order to evaluate whether an
initial cycle including at least 32 treatments during four
months (twice weekly) can modify critical parameters
including glycemic and C-reactive peptide levels, none-
nzymatic glycosilation, aldose reductase activity, advaced
glycated endproducts (AGEs) and the antioxidant-pro-
oxidant balance. Although more expensive, the precise
stoichiometry of the ozonated AHT method can give far
more precise information than the rectal insufflation.
The adopted strategy ‘start low, go slow’ appears the
most idoneous for inducing ozone tolerance and the
rebalance of the redox system [46]. Bearing in mind that
O2-O3 therapy may modify glycemic levels, a strict con-
trol of the insulin level is imperative.
A debate on a scientifically proved application of a
complementary approach based on the knowledge that
O3-AHT can abate the chronic oxidative stress, delay
serious complications and improve the quality of life of
diabetic patients has been proposed [104]) and is urgent.
4.4. Possible mechanisms for activating the immune
system by ozone therapy
T-cells serve a very important role in protecting our
body against foreign components: when the T-cell anti-
gen receptor (TCR) recognizes any foreign antigens, the
ZAP-70 molecule undergoes a tyrosine-phosphorylation,
and then activates phospholipase C g1( P L C g1) [105].
Activated PLCg1 hydrolyze phosphatidylinositol-4,5-
bisphosphate (PIP2), a membrane lipid, to produce sec-
ond messengers, inositol triphosphate (IP3) and diacyl-
glycerol (DG). IP3 binds to the inositol triphosphate
receptor (IP3R) on the endoplasmic reticulum (ER)
membrane, resulting in a release of Ca
+2 from the ER
into the cytosol. Increases in cytosolic Ca
+2 levels acti-
vate calcineurin (CN), a phosphatase dependent on Ca
+2/calmodulin, which dephosphorylates nuclear factor
activated T-cells (NFAT) and transports it into the
nucleus. NFAT then induces the transcription of cyto-
kines, such as IL-2, TNFa,I L - 6a n dI F N g, and immune
response elements on DNA, which are, then, translated
into their proteins [106]. The produced cytokines and
transcription products of immune response elements
support the immune functions of our body. NFAT is
also expressed in other cells and tissues, and can itself
combine with DNA elements. However, the combination
of NFAT with DNA is primarily induced via the coexis-
tence of activated protein-1 (AP-1), a nuclear transcrip-
tion factor. AP-1 is activated through the Ras-MAPKs
(mitogen activated protein kinases) pathway, which is
also mediated by DG.
It was previously reported that immunosuppressive
drugs, such as cyclosporine A and KF506 (tacrolimus),
can inhibit the de-phosphorylation of NFAT induced by
CN, and thereby the transportation of NFAT into the
nucleus [107]. Ca
2+-antagonists, such as anti-hyperten-
sive drugs, inhibit Ca
+2 influx into the cytosol and the
constriction of vascular smooth muscle cells. However,
several epidemiological studies suggest that prolonged
use of Ca
2+-antagonist may result in tumors or the
development of chronic diseases. Ca
2+-antagonist inhi-
bits Ca
+2 influx into cytosol of T-cells, and the activity
of CN. Thus, they also may induce the de-phosphoryla-
tion NFAT, and its transportation into the nucleus.
Consequently, the biosynthesis of cytokines would also
be inhibited. This may explain the why long-term use of
Ca
2+-antagonist may result in tumors or the develop-
ment of chronic diseases. Furthermore, it is well known
that these nuclear transcription factors are also induced
by mild oxidative stress. For example, Maziere et al
[108] found that high levels of UVA radiation inhibit
the CN-NFAT system, and low levels of UVA activate
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induced by ozone therapy may also activate NFAT and
AP-1 to then activate immune functions. This may
explain of point d) in Table 2. However it remains to be
seen whether a mild ozone therapy does really activate
the CN-NFAT system
Therefore, beside this possible pathway, it must be
kept in mind that several studies [109-111] have been
carried out by using human normal blood treated with
ozone concentrations within the “therapeutic window”.
With these parameters ozone acts on human blood
and yields a hormetic dose-response relationship with-
out any toxicity [112]. After incubation of up to 8-9
hours, the plasma was isolated and several cytokines
synthesized and released by immune cells such as
IFNg,T N F a, IL-2, IL-6 and IL-8 have been measured
and their small but consistent amounts were ozone-
concentration dependent. During each ozone therapy
session, this induced bland immuno-stimulation
regards only about 4% of the lymphocytes and mono-
cytes present in the blood exposed to ozone ex vivo
[46]. It was postulated that the small percentage of
immunocytes activated ex vivo by H2O2,v i aN F k B
may transfer the activation in vivo after the infusion
of ozonated blood into the donor patient. Indeed,
after blood infusion into the donor, the activated lym-
phocytes, by releasing cytokines, can activate other
cells in vivo [46]. If this is true, repeated therapeutic
sessions may indeed reverse a condition of immune-
depression. Actually these observations have suggested
to use ozone therapy in both acute and chronic bac-
terial and viral infections keeping in mind that all
pathogens, either free in the plasma or located intra-
cellularly, are paradoxically well protected by the
potent antioxidant capacity of blood and cells [113].
This is so, because with the ozone concentration
established by the therapeutic index, neither ozone or
its messengers can deliver a bactericidal or virucidal
effect. Indeed, contrary to what is commonly believed,
ozone can act only as a supportive therapy in infec-
tious diseases and we know already that both HIV
[114] and chronic hepatitis C infections cannot be
proficiently treated only with ozone therapy unless we
simultaneously combined with the appropriate dosages
of antiviral drugs.
Moreover we are totally at a loss to discover if ozone
therapy can be useful in autoimmune diseases, such as
rheumatoid arthritis, multiple sclerosis and psoriasis.
Once again private ozone therapists have treated these
diseases claiming positive results, which have been never
reported in medical journals. The key problem is to dis-
cover the ideal ozone concentration for quenching the
activity of cytotoxic T cells and to enhance the number
and activity of CD4+ T-Regulatory cells [46].
4.5. May ozone kill cancer cells and have therapeutic
effects?
An early paper by Sweet et al [115] elicited great enthu-
siasm having shown that ozone selectively inhibits the
growth of a variety of human cancer cells in vitro.
Unfortunately this approach does not reflect the situa-
tion in the patient because ozone as such is never able
to reach any cancer cells in vivo. Another hypothetical
possibility had been to restore normoxia and apoptosis
of tumor cells after the infusion of ozonated blood [91],
but clinical experience in pre-terminal patient with
hepatic or/and pulmonary metastasis has shown the
irreversibility of the cancer. An experimental attempt
[116] to insufflate an ozone and oxygen mixture into
the peritoneum at an advanced stage of cancer led to a
higher survival rate of treated rabbits (i.e. 7/14) versus
sham-treated rabbits (i.e. 1/7). In a letter, Bocci [117]
have suggested that these anti-tumor effects may be
induced via an ozone/oxygen-mediated activation of the
body’s immuno-surveillance, which is a real possibility
in a virgin animal. Indeed these results are evident only
in experimental oncology, particularly in mice and not
in humans where, once the cancer is discovered, the
immune system is already suppressed. To be objective,
there are a number of rather old and uncontrolled clini-
cal studies demonstrating that ozone therapy extends
the life expectancy of patients with cancer. This is partly
true in the sense that ozonated autohemotherapy
improves the quality of life as often observed [46], but is
unable to block the tumour progression. Chronic
inflammation plays a critical role in neoplastic growth
(transformation), as well as in many other diseases.
NFB is activated by various inflammatory factors, such
as LPS and severe oxidative stress derived from drugs
that induce iNOS, COX-2, and inflammatory cytokines.
These factors induce the survival, growth, and prolifera-
tion of tumor cells, and result in neoplasia [118]. There-
fore, inhibition of NFB is an important target for the
prevention and treatment of cancer. For example, it is
known that the inhibitors of NFB, such as vitamin E,
resveratrol, curcumin, catechin, and aspirin may have
some effects in slowing tumor growth.
4.6. A possible mechanism by which ozone therapy
improves neurodegenerative diseases
The pathogenesis of neurodegenerative diseases is signif-
icantly associated with oxidative stress. Increased oxida-
tive stress is also associated with neuronal cell death
during the pathogenesis of multiple chronic neurode-
generative diseases, including Alzheimer’sd i s e a s e( A D ) ,
Parkinson’s disease (PD), Huntington’s disease (HD),
and amyotrophic lateral sclerosis (ALS). It was found
that the Nrf2/ARE pathway protects against neurode-
generation [81,119] as mentioned previously. Figure 2
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ronal cells and death of Nigral cells induced via ROS.
Increases in ROS result in mitochondrial dysfunction
and neuro-inflammation, a common denominator of
PD. On the other hand, Nrf2 acts as an emerging target
to counteract mitochondrial dysfunction and inflamma-
tion. Nrf2 activates the antioxidant response element
(ARE) pathway, including a battery of cytoprotective
genes, such as antioxidants and anti-inflammatory
genes, and several transcription factors involved in mito-
chondrial biogenesis [119].
Jazwa et al [82] also found that Nrf2 and HIF-1a play
a crucial role in neuroprotection and suppression of
neuroinflammation in neurodegenerative diseases, espe-
cially through the activation of HO-1 via the Nrf2/ARE
pathway (for HO-1 see also Idriss et al. [120]). Further-
more, drugs activating Nrf2 may also be good candi-
dates for inducing HO-1, in concert with other
antioxidant and detoxification enzymes. In fact, it was
previously reported that there are many phytochemicals
that are effective in protecting against neurodegenerative
diseases [121-124]. These findings may explain the ratio-
nale (point g) in Table 1. Thus, further investigation
into the effects of ozone therapy in activating the Nrf2/
ARE pathway is warranted. Indeed several anecdotal
observations have been done by private ozone therapists
performing ozonated AHT in patients with initial Alz-
heimer’s disease. It is unfortunate that these promising
observation have been never published and therefore the
precise parameters remain unknown. Once again ortho-
dox medicine remains skeptical about the value of
ozone therapy and this make progress very difficult.
4.7. The topical use of ozone therapy in skin and mucosal
infections and lesions
Regarding both cutaneous and mucosal infections and
lesions, both ozonated water and different gradation of
standardized ozonated vegetable oils will be used twice
daily until complete healing. Both ozonated water and
oils have been already proved to be excellent disinfec-
tants and healing stimulators, more effective than topical
antibiotics, growth factors, only oxygenation, maggot and
negative pressure wound therapies. In conclusion, this
paper aims to emphasize the possibility of a new
approach for improving the gloomy prognosis of the dia-
betic foot, ischemic ulcers and necrosis, decubitus,
abscesses, anal fissures, fistulae, aphthae, inveterate
osteomyelitis stomatitis, vulvovaginitis and onycomyco-
sis. There are experimental studies [125,126] clearly
showing the advantages of using ozonated oils and a
great number of pertinent patents have been reviewed
[127,128]. Any wound or lesions must firstly be cleaned
possibly with ozonated water or diluted H2O2 solution,
because the removal of purulent material or fibrin or
necrotic cells markedly reduces the effect of ozonated oil
because of the residual presence of biological substances
Figure 2
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mental attitude to profitably use ozonated oil, but once a
patient has tried that, he will continue to use it.
4.8. The problem of backache and orthopedic diseases
has been successfully solved with ozone
In reality the use of ozone in hernial disk is a real
breakthrough and, while the use of ozonated AHT is
still regarded with suspicion, the application of ozone in
low back pain is practically accepted world-wide. During
lifetime low back pain is a common disturbing symp-
toms that can affect up to 80% of the population at least
once. Under radioscopic control, 3 to 7 ml of the gas
mixture (usually ozone 3% and oxygen 97%), with an
ozone concentration of 30-35 μg/ml are directly admi-
nistered into the centre of the intersomatic space corre-
sponding to the disc herniation [129]. An expert
neurosurgeon can do it in about ten minutes and, after
a suitable rest, the patient frequently gets up amazed by
the disappearance of pain.
What are the mechanisms of action ? They are quite
different from those of ozone in blood. Ozone readily
dissolves in the water of the nucleus pulposus and reacts
with macromolecular glycoproteins composed of carbo-
hydrates and polypeptide chains, namely proteoglycans
and collagen types II and IV. Formation of ROS is likely
followed by generation of hydroxyl radicals according to
the Fenton’s reaction:
H2O2 +F e ++ −−−−−−→ OH◦ +O H − +F e +++
because traces of catalytic iron ions can easily be
released from the needle during the injection. By using
the Electron Paramagnetic Resonance (EPR) spin trap-
ping technique, the transitory formation of hydroxyl
radical, which has a half life of 1 × 10
-9 sec at 37°C,
has been demonstrated [130]. The hydroxyl radical is
the most reactive radical attacking and breaking down
any biomolecule within its reach: the rapid reabsorp-
tion of hydrolytic products and free water lead to a
progressive shrinkage of the nucleus and frequently to
a progressive disappearance of the herniated material.
The inflammatory process induced by the hernia disap-
pears thereafter.
An even simpler and popular approach for treating the
low back pain is the administration of gas into the para-
vertebral muscles corresponding either to trigger points
or to the metamers of the herniated disk. It is an easy
approach consisting in one, or up to four injections of
5-10 ml of the gas mixture per site performed very
slowly. The ozone concentration must not exceed 20-25
μg/ml, because it is painful. While the first is a direct
procedure, this one is an indirect one also named as “a
chemical acupuncture” by Bocci [50]. The mechanisms
of action of the indirect methods have been amply dis-
cussed [131] and the therapeutic benefit is almost 80%
for the direct procedure and about 73% for the chemical
acupuncture. So far both methodologies have been
applied from Canada to China, India and Europe and
almost a million people have benefited from it.
4.9. The use of ozone in Dentistry
This is another surprising use of ozone mostly used in
children for treating primary carious lesions using a spe-
cial device isolating the tooth which is treated with
ozone-oxygen for about 60 sec. This procedure sterilizes
the dental lesions and allows the re-mineralization of
the tooth. The procedure was invented and propagated
by prof. Edward Lynch [132] and it was defined as “The
revolution in Dentistry”
5. Quality of Life (QOL) following ozone therapy
Ozone therapy is proposed to procure a surprising well-
ness in most patients, in part, via the stimulation of the
neuroendocrine system. The mechanisms by which
ozone therapy stimulates the neuroendocrine system are
not yet clear. However, it was recently reported [133]
that the vulnerability of neuroendocrine cells induced
via mitochondrial and oxidative stress is associated with
the inhibition of the Nrf2/ARE/Keap1 antioxidant path-
way, and decreased expression of antioxidant and phase
I/II conjugation enzymes, most of which are Nrf2 tran-
scriptional targets neuroendocrine system was also
found to be associated with the Nrf2 pathway. It is
unfortunate that so far it has not been possible to com-
paratively evaluate the intensity and shape of the circa-
dian rhythm of ACTH, cortisol, growth hormone and
dehydro-epi-androsterone (DHEA), in normal volunteers
before and after ozonated AHT. Moreover it has been
postulated a release of endorphins and possibly an
increased release of serotonin for explaining the feeling
of euphoria and well-being post ozone therapy
Obviously a medical evaluation on the QOL on
ozone therapy is necessary. To date, Di Paolo et al.,
[94] only group to report on the QOL after extravascu-
lar blood ozonation and a prostaglandin analogue in
POAD patients, that was in accordance with the Inter-
national Quality of Life Assessment (IQOLA). Patients
were scored from 0 to 4 on claudication, pain, pruri-
tus, heavy of legs, general well-being, insomnia, appe-
tite, weakness, sight, healing, digestion and joint pain.
EBOO therapy demonstrated an excellent QOL. Thus,
such QOL evaluations are important, as they also may
clarify if ozone therapy is effective. Regarding the ozo-
nated AHT, besides one venipuncture, the QOL eva-
luation is even better with minimal, if any, side effects
[46,134,135].
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During the last four decades million of O3-AHT have been
performed in Europe without any problem and the
recorded four deaths [135] were due to direct intravenous
administration of O2-O3, a practice prohibited since 1984.
Ozone, generated extempore from medical oxygen, must
be used immediately and represents about 3% of the gas
mixture. Erythrocytes, after ozonization, maintain their
usual life-span in the circulation [46]. The method using
neutral, sterile glass bottles under vacuum is absolutely
toxic-free, the cost of the disposable set for each treatment
is fifteen euros and a trained nurse can easily perform the
whole procedure in about 35 min [56]. The only inconve-
nience is the venipuncture to which patients are nonethe-
less compliant. It must be emphasized that the treatment
is not only perfectly tolerated but most age-related macu-
lar degeneration (ARMD) and vasculopathic patients have
reported a feeling of wellness and euphoria throughout
the cycle. This fact explains why the compliance of the
patients remains excellent throughout the years. Almost
needless to say that if ozone therapy improves the patolo-
gic condition, it must be continued by adopting the main-
tenance therapy (two-three monthly sessions) for an
undefined period.
The application of ozone therapy in all public hospi-
tals is still being delayed by prejudice, no fundings, com-
mercial competition by big Pharma and above all by the
incomprehensible disinterest, if not plain obstruction, by
Health Authorities such as the FDA in USA and the
European Medical Association. On the contrary it is
commonly used in Russia, Ukraine and China where
most of the patients are treated with ozone therapy.
Ozone is inexpensive and no patentable and it is regret-
ful that local Health Authorities, continuously con-
cerned by the increased medical costs, do not want to
take advantage of this inexpensive procedure. Unlike
other complementary approaches, all biochemical, phy-
siological and pharmacological mechanisms elicited by
ozone are in the realm of orthodox medicine. There is
already good evidence that ozone therapy is more useful
in chronic limb ischemia than the golden standard
(prostacyclin analogues) and patients with skin lesions
are very grateful for being able to use ozonated oil. A
scheme of bland ozone therapy associated to a correct
life-style has been proposed for delaying aging [46,136].
As it has happened for other innovative medical
approaches, thanks for the efforts of many expert physi-
cians, ozone therapy will be eventually accepted by
orthodox medicine. But this will happen only when, by
performing randomized and well controlled clinical
trials in suitable diseases, its validity and atoxicity will
unequivocally be demonstrated.
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